UA94403C2 - Человеческое моноклональное антитело, которое нейтрализует gm-csf - Google Patents

Человеческое моноклональное антитело, которое нейтрализует gm-csf

Info

Publication number
UA94403C2
UA94403C2 UAA200712125A UAA200712125A UA94403C2 UA 94403 C2 UA94403 C2 UA 94403C2 UA A200712125 A UAA200712125 A UA A200712125A UA A200712125 A UAA200712125 A UA A200712125A UA 94403 C2 UA94403 C2 UA 94403C2
Authority
UA
Ukraine
Prior art keywords
monoclonal antibody
human monoclonal
stimulating factor
colony stimulating
macrophage colony
Prior art date
Application number
UAA200712125A
Other languages
English (en)
Ukrainian (uk)
Inventor
Тобиас Раум
Хепп, (Нее Хенкель) Юлия
Ева Фисер
Петш, (Нее Миттельстрасс) Силке
Стивен Земан
Андреас Вольф
Сандра Брукмайер
Original Assignee
Микромет Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Микромет Аг filed Critical Микромет Аг
Publication of UA94403C2 publication Critical patent/UA94403C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)

Abstract

Изобретение относится к человеческому моноклональному антителу или его фрагменту, который специфически связывается с эпитопом, преимущественно прерывчатым эпитопом, и нейтрализует GM-CSF приматов, где эпитоп включает аминокислоты 23-27 (RRLLN) и аминокислоты 65-77 (GLR/QGSLTKLKGPL). Изобретение также относится к молекуле полинуклеотида, который кодирует указанное антитело, фармацевтической композиции, а также применению данного антитела в производстве лекарственного средства для лечения воспалительных заболеваний, лечения опухолевого заболевания или другого состояния, которое характеризуется задержкой апоптоза клеток, увеличенным выживанием или пролиферацией клеток.
UAA200712125A 2005-04-18 2006-04-18 Человеческое моноклональное антитело, которое нейтрализует gm-csf UA94403C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05008410 2005-04-18

Publications (1)

Publication Number Publication Date
UA94403C2 true UA94403C2 (ru) 2011-05-10

Family

ID=37115507

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200712125A UA94403C2 (ru) 2005-04-18 2006-04-18 Человеческое моноклональное антитело, которое нейтрализует gm-csf

Country Status (29)

Country Link
US (3) US8017748B2 (ru)
EP (2) EP2468774A3 (ru)
JP (1) JP5085533B2 (ru)
KR (2) KR20150091193A (ru)
CN (2) CN103342751B (ru)
AU (1) AU2006237159B2 (ru)
BR (1) BRPI0608281B8 (ru)
CA (1) CA2605402C (ru)
CY (1) CY1116632T1 (ru)
DK (1) DK1874819T3 (ru)
EA (2) EA017420B9 (ru)
ES (1) ES2545769T3 (ru)
HK (2) HK1112003A1 (ru)
HR (1) HRP20150773T1 (ru)
HU (1) HUE025134T2 (ru)
IL (2) IL186486A0 (ru)
ME (1) ME02191B (ru)
MX (1) MX2007012569A (ru)
NO (1) NO344249B1 (ru)
NZ (1) NZ562093A (ru)
PL (1) PL1874819T3 (ru)
PT (1) PT1874819E (ru)
RS (1) RS54127B1 (ru)
RU (2) RU2458071C2 (ru)
SG (1) SG161292A1 (ru)
SI (1) SI1874819T1 (ru)
UA (1) UA94403C2 (ru)
WO (1) WO2006111353A2 (ru)
ZA (1) ZA200708201B (ru)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1874819T1 (sl) 2005-04-18 2015-09-30 Amgen Research (Munich) Gmbh Protitelesni nevtralizatorji humanega faktorja stimulacije kolonij granulocitov makrofagov
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN101501070B (zh) 2006-02-08 2013-12-25 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
AU2008214344B2 (en) * 2007-02-08 2012-06-07 Merck Sharp & Dohme Corp. Antibodies specific for Dkk-1
EP2160407A4 (en) * 2007-05-23 2011-07-27 Crc For Asthma And Airways Ltd NEUTRALIZING ANTIBODIES
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
ES2401536T3 (es) * 2007-11-13 2013-04-22 Evec Inc. Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden
DK2708559T3 (en) * 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
CA2722137C (en) * 2008-04-28 2019-03-19 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
CN102014958A (zh) * 2008-04-29 2011-04-13 米克罗麦特股份公司 用于治疗的gm-csf和il-17抑制剂
CN106397591A (zh) 2008-12-22 2017-02-15 墨尔本大学 骨关节炎治疗
US8475796B2 (en) 2008-12-22 2013-07-02 University Of Melbourne Method of treating pain using an antagonist of GM-CSF
US20120116059A1 (en) * 2009-05-05 2012-05-10 Morphosys Ag Treatment For M Treatment For Multiple Sclerosis
BR112013021526B1 (pt) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
CA2839513A1 (en) 2011-07-06 2013-01-10 Morphosys Ag Therapeutic combinations of anti - cd20 and anti - gm - csf antibodies and uses thereof
WO2013090989A1 (en) * 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
WO2015028657A1 (en) 2013-08-30 2015-03-05 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
WO2015028666A1 (en) * 2013-08-30 2015-03-05 Takeda Gmbh Neutralizing antibody or a fragment thereof specifically binding primate gm-csf for use in the treatment and/or prevention of psoriasis
ES2764833T3 (es) 2013-10-11 2020-06-04 The United States Of America Represented By The Sec Dep Of Health And Human Services Anticuerpos contra TEM8 y su uso
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US11173208B2 (en) * 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
EP3875481A1 (en) 2014-11-14 2021-09-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
WO2016079277A1 (en) * 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist in the treatment of an infectious disease
WO2016079276A1 (en) * 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease
EP3261665A1 (en) 2015-02-24 2018-01-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
PL3271389T3 (pl) 2015-03-20 2020-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizujące przeciwciała wiążące się z gp120 i ich stosowanie
US10392441B2 (en) 2015-10-07 2019-08-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
CN115010805A (zh) 2015-11-03 2022-09-06 美国政府(由卫生和人类服务部的部长所代表) Hiv-1 gp41中和抗体及其用途
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
CN106872428A (zh) * 2017-02-07 2017-06-20 远见生物科技（上海）有限公司 一种用于检测中性粒细胞呼吸爆发功能的试剂盒
US11021535B2 (en) 2017-02-10 2021-06-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US10870703B2 (en) 2017-10-02 2020-12-22 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11084888B2 (en) 2017-10-24 2021-08-10 ASM, Inc. Production method for low inclusion rate polyrotaxane
EP3724223A1 (en) 2018-01-02 2020-10-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
AU2019226034A1 (en) 2018-02-21 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 Env and their use
JP2022503637A (ja) * 2018-10-15 2022-01-12 エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド 顆粒球マクロファージコロニー刺激因子に対する抗体及びそれらの使用
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
EP3883609A2 (en) 2018-12-20 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
EP3962523A2 (en) 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
EA202290208A1 (ru) 2019-07-02 2022-03-25 Дзе Юнайтед Стейтс Оф Эмерика, Эз Репрезентед Бай Дзе Секретэри, Дипартмент Оф Хелт Энд Хьюман Сервисиз МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
IL304955A (en) 2021-02-09 2023-10-01 Us Health Antibodies targeting the spike protein of a coronavirus
CA3210753A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
CA3232223A1 (en) 2021-09-17 2023-03-23 Ying Fu Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8624899D0 (en) * 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
US5070013A (en) 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
WO1998048008A1 (en) 1997-04-23 1998-10-29 Plueckthun Andreas Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
NZ507381A (en) 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
WO2001058459A1 (en) * 2000-02-14 2001-08-16 Mitsubishi Pharma Corporation Remedies for hepatitis c
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003217386B2 (en) * 2002-02-13 2008-06-26 Ludwig Institute For Cancer Research Humanized GM-CSF antibodies
EP1593690B1 (en) * 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
SI1874819T1 (sl) * 2005-04-18 2015-09-30 Amgen Research (Munich) Gmbh Protitelesni nevtralizatorji humanega faktorja stimulacije kolonij granulocitov makrofagov
NZ564027A (en) 2005-05-18 2011-06-30 Morphosys Ag Anti-GM-CSF antibodies and uses therefor
CN101501070B (zh) 2006-02-08 2013-12-25 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体

Also Published As

Publication number Publication date
EP2468774A2 (en) 2012-06-27
US10138297B2 (en) 2018-11-27
US20160130338A1 (en) 2016-05-12
RU2007138341A (ru) 2009-05-27
BRPI0608281A2 (pt) 2009-12-15
RU2012115683A (ru) 2013-10-27
CY1116632T1 (el) 2017-03-15
EP1874819A2 (en) 2008-01-09
KR101704809B1 (ko) 2017-02-08
IL186486A0 (en) 2008-01-20
EA013162B1 (ru) 2010-02-26
ZA200708201B (en) 2008-07-30
BRPI0608281B1 (pt) 2020-01-28
PT1874819E (pt) 2015-09-17
CA2605402A1 (en) 2006-10-26
HUE025134T2 (en) 2016-01-28
US9067993B2 (en) 2015-06-30
CN101184777B (zh) 2013-07-17
SI1874819T1 (sl) 2015-09-30
EP1874819B1 (en) 2015-05-27
ES2545769T3 (es) 2015-09-15
CN103342751B (zh) 2015-12-23
US20090297532A1 (en) 2009-12-03
BRPI0608281B8 (pt) 2021-05-25
EP2468774A3 (en) 2013-01-02
RS54127B1 (en) 2015-12-31
NO344249B1 (no) 2019-10-21
JP5085533B2 (ja) 2012-11-28
CN103342751A (zh) 2013-10-09
IL220412A0 (en) 2012-07-31
KR20080005962A (ko) 2008-01-15
US8017748B2 (en) 2011-09-13
NO20075802L (no) 2008-01-10
MX2007012569A (es) 2007-12-06
AU2006237159B2 (en) 2011-03-24
WO2006111353A2 (en) 2006-10-26
HRP20150773T1 (hr) 2015-08-28
CA2605402C (en) 2017-05-23
PL1874819T3 (pl) 2015-10-30
EA017420B1 (ru) 2012-12-28
US20120009195A1 (en) 2012-01-12
NZ562093A (en) 2011-01-28
EA200702008A1 (ru) 2008-06-30
AU2006237159A1 (en) 2006-10-26
IL220412A (en) 2017-04-30
SG161292A1 (en) 2010-05-27
DK1874819T3 (en) 2015-08-31
JP2008536505A (ja) 2008-09-11
RU2458071C2 (ru) 2012-08-10
HK1112003A1 (en) 2008-08-22
HK1190161A1 (zh) 2014-06-27
KR20150091193A (ko) 2015-08-07
EA200901500A1 (ru) 2010-10-29
CN101184777A (zh) 2008-05-21
WO2006111353A3 (en) 2007-04-19
ME02191B (me) 2016-02-20
EA017420B9 (ru) 2013-03-29

Similar Documents

Publication Publication Date Title
UA94403C2 (ru) Человеческое моноклональное антитело, которое нейтрализует gm-csf
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
MY149630A (en) Antibodies against amyloid-beta peptide
NZ593173A (en) Osteonectin (Secreted Protein, Acidic, Rich in Cysteines (SPARC)) binding ScFvS
HK1222870A1 (zh) 用於治療與細胞因子信號傳導有關的疾病和病症、涉及與 結合的抗體的組合物和方法
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
NZ602166A (en) Antibodies to il-6 and use thereof
MX2009005597A (es) Miembros de enlace para interleucina 6.
EA201100694A1 (ru) Антитело к cd38 человека и его применение
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX355181B (es) Anticuerpos humanos contra el factor tisular.
WO2007025977A8 (en) Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
MX337590B (es) Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias.
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
WO2010021874A3 (en) Engineered anti-il-13 antibodies, compositions, methods and uses
EP2444491A3 (en) Hyperglycosylated human coagulation factor IX
HK1122803A1 (ru)
IL180364A (en) Use of antibodies specifically related to amyloid-beta peptide in the manufacture of drugs for the treatment of diseases characterized by amyloid-beta deficiency, pharmaceutical compositions including them and methods for their preparation and methods for use thereof
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007064727A3 (en) Penetrabodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
UA96141C2 (ru) Нейтрализующее антитело, которое имеет специфичность к человеческому il-6
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
EA201200975A1 (ru) Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение